Human FcγRI (CD64) is an integral membrane glycoprotein functioning as a high-affinity receptor binding to monomeric IgG. In this study, the extracellular region of FcγRI, which is the actual part that interacts with IgG, was expressed as aglycosylated recombinant human FcγRI (rhFcγRI) in Escherichia coli. The soluble form of aglycosylated rhFcγRI was expressed in the periplasm of E. coli. The production of soluble aglycosylated rhFcγRI was increased by low induction levels. Furthermore, this production was increased by low translational efficiency, controlled by modification of the putative region between the ribosome binding site and initiation codon of rhFcγRI fusing signal peptide (MalE, PelB, or TorT) of the expression vector. By the optimization of induction and translational efficiency, the production of soluble aglycosylated rhFcγRI was up to approximately 0.8 mg/l of culture medium. Surface plasmon resonance analysis revealed that the binding affinities of aglycosylated rhFcγRI for human IgG1 (equilibrium dissociation constant K D =[1.7±0.2]×10−10 M) and IgG3 (K D=[1.1±0.2]×10−10 M) were similar to those of glycosylated rhFcγRI.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00253-012-3902-xDOI Listing

Publication Analysis

Top Keywords

aglycosylated rhfcγri
16
soluble aglycosylated
12
translational efficiency
12
aglycosylated recombinant
8
recombinant human
8
low translational
8
escherichia coli
8
human fcγri
8
production soluble
8
increased low
8

Similar Publications

Monoclonal antibodies (mAbs) are a major class of biopharmaceuticals manufactured by well-established processes using Chinese Hamster Ovary (CHO) cells. Next-generation biomanufacturing using alternative hosts like Komagataella phaffii could improve the accessibility of these medicines, address broad societal goals for sustainability, and offer financial advantages for accelerated development of new products. Antibodies produced by K.

View Article and Find Full Text PDF

Fcγ receptors (FcγR) are responsible for many of the interactions between immunoglobulins (IgG) and immune cells. In biomedicine, this interplay is critical to the activity of several types of immunotherapeutics; however, relatively little is known about how FcγRs affect the in vivo performance of radiolabeled antibodies. A handful of recent preclinical studies suggest that binding by FcγR-and particularly FcγRI-can affect the pharmacokinetic profiles of Zr-labeled radioimmunoconjugates, but there are no extant studies in immunocompetent or genetically engineered mouse models of cancer.

View Article and Find Full Text PDF

evaluation of the role of Fab glycosylation in cetuximab antibody dynamics.

Front Immunol

August 2024

Analytical Excellence and Program Management, Merck Serono S.p.A., Rome, Italy.

Introduction: N-glycosylation is a post-translational modification that is highly important for the development of monoclonal antibodies (mAbs), as it regulates their biological activity, particularly in terms of immune effector functions. While typically added at the Fc level, approximately 15-25% of circulating antibodies exhibit glycosylation in the Fab domains as well. To the best of our knowledge, cetuximab (Erbitux) is the only therapeutic antibody presenting Fab glycosylation approved world-wide targeting the epidermal growth factor receptor for the treatment of metastatic-colorectal and head and neck cancers.

View Article and Find Full Text PDF
Article Synopsis
  • The self-association of therapeutic antibodies can lead to high viscosity, complicating manufacturing and limiting subcutaneous delivery, with previous solutions focusing on variable domain mutations and excipients.
  • This study examined various Fc mutations on the viscosity of two IgG antibodies: omalizumab (anti-IgE) and trastuzumab (anti-HER2), revealing that certain Fc modifications significantly reduced omalizumab's high viscosity (from 176 cP).
  • Molecular dynamics simulations provided insights into how these Fc mutations affect the antibodies' electrostatic and hydrophobic properties, suggesting that optimizing Fc mutations could improve future antibody therapies for easier subcutaneous administration.
View Article and Find Full Text PDF

Prostate-specific antigen (PSA) levels are widely used to screen for prostate cancer, yet the test has poor sensitivity, specificity and predictive value, which leads to overdiagnosis and overtreatment. Alterations in the glycosylation status of PSA, including fucosylation, may offer scope for an improved biomarker. We sought to generate a monoclonal antibody (mAb) targeting α-1,6-fucosylated PSA (fuc-PSA) and to develop a tissue-based immunological assay for fuc-PSA detection.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!